David Aggen

David H. Aggen, MD, PhD, is a medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center, focusing on defining adaptive immune resistance mechanisms and developing novel immunotherapy modalities in bladder cancer. He completed an MD and PhD at the University of Illinois College of Medicine, where he studied the molecular basis of T cell recognition in response to cancer and developed TCR based T cell therapies for cancer cell therapies. Dr. Aggen joined the faculty at MSKCC as an Assistant Attending Physician on the genitourinary oncology service in 2019, where his primary research focus is on bladder cancer. He is the principal investigator for an investigator-initiated trial evaluating enfortumab vedotin and pembrolizumab before radical cystectomy for patients with lymph node-positive bladder cancer (EV-ECLIPSE trial). His translational research focus is understanding the immunogenic effects of antibody drug-conjugates (ADCs), understanding ADC target expression in urothelial cancer, and developing next-generation treatments for ADC-resistant bladder cancers. At MSK, he has received funding from an ASCO Career Development Award, a DoD career-development award, and from Equinox Cycle-4-Survival to define mechanisms of response and resistance to ADC therapy and design next-generation immunotherapies to treat bladder cancer. He is also the MSK site principal investigator for perioperative and adjuvant immunotherapy trials for high-risk bladder cancer.